Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
14. Oktober 2021 01:30 ET
|
Adocia
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to...
Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
10. September 2021 01:30 ET
|
Adocia
LYON, France, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic...
Adocia在1型糖尿病患者中启动BC LisPram通过泵给药的1期临床试验
29. Juni 2021 12:00 ET
|
Adocia SA
首次在单个泵中测试与血糖控制相关的两个关键激素，即速效胰岛素类似物和淀粉类似物的独特组合，BioChaperone® 赖脯胰岛素和普兰林肽联合制剂的安全性、药代动力学和血糖控制能力将与赖脯胰岛素进行比较 里昂, June 30, 2021 (GLOBE NEWSWIRE) -- Adocia (巴黎泛欧交易所: FR0011184241 – ADOC),...
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
29. Juni 2021 12:00 ET
|
Adocia SA
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
29. Juni 2021 12:00 ET
|
Adocia
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81ˢᵗ Scientific Sessions
15. Juni 2021 01:30 ET
|
Adocia
LYON, France, June 15, 2021 (GLOBE NEWSWIRE) -- ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of...
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
26. Mai 2021 01:30 ET
|
Adocia
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...